New Test Helps Spot Bladder Cancer
Quick Urine Test Helped Detect Bladder Cancer's Return
Jan. 17, 2006 -- A new urine test helps identify bladder cancer recurrences, with results available before a patient leaves their doctor's office.
So says a study in The Journal of the American Medical Association. The researchers included H. Barton Grossman, MD, of the University of Texas M.D. Anderson Cancer Center.
The test, called BladderChek, screens urine for high levels of a protein called NMP22. Results are available within an hour, without extra lab work or special training for medical staff.
The test enhances -- but doesn't replace -- other screening methods, the researchers write.
'Good News for Patients'
Barry Stein, MD, worked on the study and commented on it in a news release.
"This is good news for patients," says Stein, a professor of urology at Brown Medical School and surgeon-in-chief of urology at Rhode Island Hospital in Providence, R.I.
"If you have been treated for bladder cancer and are being monitored for recurrence, the accuracy of your diagnosis is extremely important," Stein continues.
Stein says it's too soon to know if the BladderChek test should be used on its own, replacing other screening methods.
"We need to do further research," he says. "But if a test is developed that is effective as a standalone, that would be a real benefit."
Watching for Recurrence
More than half a million people in the U.S. have had bladder cancer, making it the country's fifth most common cancer, write Grossman and colleagues.
The chances of getting bladder cancer more than once are high -- about 50% to 90%, depending on the cancer's stage, grade, and original tumors, the researchers note. With odds like that, rigorous, repeated screening is recommended to check for recurrences.
The main test, called cystoscopy, uses a tiny scope to examine the inside of the bladder and is considered the gold standard. Another test, called cytology, checks urine for abnormal changes in intact bladder cells.
Cytology's lab work takes time and the test isn't always as sensitive as doctors would like, especially with low-grade or early cancers, write the researchers. They note that no single test is flawless, so more than one method is usually used.